- Home
- CISS vs KPRX Comparison
CISS vs KPRX Comparison
Compare CISS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- KPRX
- Stock Information
- Founded
- CISS 2022
- KPRX 1998
- Country
- CISS Greece
- KPRX United States
- Employees
- CISS N/A
- KPRX N/A
- Industry
- CISS Marine Transportation
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CISS Consumer Discretionary
- KPRX Health Care
- Exchange
- CISS Nasdaq
- KPRX Nasdaq
- Market Cap
- CISS 11.9M
- KPRX 11.0M
- IPO Year
- CISS N/A
- KPRX N/A
- Fundamental
- Price
- CISS $1.09
- KPRX $3.38
- Analyst Decision
- CISS
- KPRX Strong Buy
- Analyst Count
- CISS 0
- KPRX 1
- Target Price
- CISS N/A
- KPRX $10.00
- AVG Volume (30 Days)
- CISS 110.7K
- KPRX 45.3K
- Earning Date
- CISS 11-19-2024
- KPRX 11-19-2024
- Dividend Yield
- CISS N/A
- KPRX N/A
- EPS Growth
- CISS N/A
- KPRX N/A
- EPS
- CISS N/A
- KPRX 1.53
- Revenue
- CISS $47,503,090.00
- KPRX $16,020,000.00
- Revenue This Year
- CISS N/A
- KPRX N/A
- Revenue Next Year
- CISS N/A
- KPRX N/A
- P/E Ratio
- CISS N/A
- KPRX $2.29
- Revenue Growth
- CISS 264.29
- KPRX N/A
- 52 Week Low
- CISS $1.08
- KPRX $3.00
- 52 Week High
- CISS $68.50
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- CISS 38.87
- KPRX 43.73
- Support Level
- CISS $1.13
- KPRX $3.47
- Resistance Level
- CISS $1.17
- KPRX $3.75
- Average True Range (ATR)
- CISS 0.05
- KPRX 0.22
- MACD
- CISS -0.01
- KPRX -0.03
- Stochastic Oscillator
- CISS 6.67
- KPRX 0.00
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.